These data may shed light on the anti-glioblastoma mechanisms of decorin described in this report and previous studies [21,23,68], and suggest that dsAAV-decorin could be a potential candidate for gene therapy in patients with malignant glioma, and as an adjuvant for other modalities of glioma therapy. Here, DCN is linked to glioma.